Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TL-023
- Development stage
- Preclinical
- Lead developer
- TrueLab Biopharmaceutical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
TL-023 is a discovery-stage, half-life extended (HLE) fusion protein developed by TrueLab Biopharmaceutical. It is designed to target the Transmembrane activator and CAML interactor (TACI) signaling pathway, which plays a critical role in B-cell maturation and survival. The drug is being developed for the treatment of B-cell mediated autoimmune and renal diseases, including IgA Nephropathy (IgAN), Systemic Lupus Erythematosus (SLE), and Lupus Nephritis (LN). By modulating these pathways, TL-023 aims to reduce the production of pathogenic autoantibodies and inflammatory cytokines. The fusion protein architecture is engineered to provide an extended half-life, potentially allowing for improved therapeutic efficacy and patient convenience compared to non-extended versions.
02
Targets
TNFSF13 (APRIL)BAFF (Tumor necrosis factor ligand superfamily member 13B)FCGRT (Neonatal crystallizable fragment receptor)TACI (Tumor necrosis factor receptor superfamily member 13B)
Beyond the preview
Go deeper on TL-023.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TL-023.